Free Trial
TSE:TRIL

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

Trillium Therapeutics logo

About Trillium Therapeutics Stock (TSE:TRIL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
60,423 shs
Average Volume
166,586 shs
Market Capitalization
C$2.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Stock News Headlines

Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousands of smart, forward-thinking individuals are making the move—out of the system and into real, untouchable assets. Because once your funds are frozen, it’s too late.
SYRE Spyre Therapeutics, Inc.
See More Headlines

TRIL Stock Analysis - Frequently Asked Questions

Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), Toronto-Dominion Bank (TD), Meta Platforms (META), Moderna (MRNA), Shopify (SHOP), Tesla (TSLA) and Bank of Nova Scotia (BNS).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:TRIL
Previous Symbol
TSE:SSS
CIK
N/A
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$43,000.00
Price / Cash Flow
9.77
Book Value
C$2.17 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$2.45 billion
Optionable
Not Optionable
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (TSE:TRIL) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners